JPWO2022220227A1 - - Google Patents

Info

Publication number
JPWO2022220227A1
JPWO2022220227A1 JP2023514646A JP2023514646A JPWO2022220227A1 JP WO2022220227 A1 JPWO2022220227 A1 JP WO2022220227A1 JP 2023514646 A JP2023514646 A JP 2023514646A JP 2023514646 A JP2023514646 A JP 2023514646A JP WO2022220227 A1 JPWO2022220227 A1 JP WO2022220227A1
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2023514646A
Other languages
Japanese (ja)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of JPWO2022220227A1 publication Critical patent/JPWO2022220227A1/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2023514646A 2021-04-14 2022-04-12 Ceased JPWO2022220227A1 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021068414 2021-04-14
PCT/JP2022/017548 WO2022220227A1 (ja) 2021-04-14 2022-04-12 テトラヒドロピリドピリミジン化合物

Publications (1)

Publication Number Publication Date
JPWO2022220227A1 true JPWO2022220227A1 (uk) 2022-10-20

Family

ID=83640095

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023514646A Ceased JPWO2022220227A1 (uk) 2021-04-14 2022-04-12

Country Status (3)

Country Link
JP (1) JPWO2022220227A1 (uk)
TW (1) TW202304908A (uk)
WO (1) WO2022220227A1 (uk)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008083367A2 (en) * 2006-12-29 2008-07-10 Rigel Pharmaceuticals, Inc. Polycyclic heteroaryl substituted triazoles useful as axl inhibitors
ES2537480T3 (es) * 2008-07-09 2015-06-08 Rigel Pharmaceuticals, Inc. Triazoles sustituidos con heteroarilo policíclicos útiles como inhibidores de Axl
BRPI1007046B1 (pt) * 2009-01-16 2019-07-16 Rigel Pharmaceuticals, Inc. Inibidores axl para uso em terapia de combinação para evitar, tratar ou controlar o câncer metastático.
EP2693881B1 (en) * 2011-04-01 2019-09-04 University of Utah Research Foundation Substituted n-phenylpyrimidin-2-amine analogs as inhibitors of the axl kinase
EP2780338B1 (en) * 2011-11-14 2016-11-09 Ignyta, Inc. Uracil derivatives as axl and c-met kinase inhibitors
BR112014018702B1 (pt) * 2012-01-31 2021-12-14 Daiichi Sankyo Company, Limited Composto, cristal, inibidor, medicamento, composição farmacêutica, e, uso de um composto ou sal
TWI649308B (zh) * 2013-07-24 2019-02-01 小野藥品工業股份有限公司 喹啉衍生物
ME03775B (me) * 2014-02-04 2021-04-20 Astellas Pharma Inc Medicinska kompozicija koja obuhvata diamino heterociklično jedinjenjekarboksamida kao aktivni sastojak
TWI723572B (zh) * 2014-07-07 2021-04-01 日商第一三共股份有限公司 具有四氫吡喃基甲基之吡啶酮衍生物及其用途
EP3233829B1 (en) * 2014-12-18 2019-08-14 Pfizer Inc Pyrimidine and triazine derivatives and their use as axl inhibitors

Also Published As

Publication number Publication date
WO2022220227A1 (ja) 2022-10-20
TW202304908A (zh) 2023-02-01

Similar Documents

Publication Publication Date Title
BR112023005462A2 (uk)
BR112023012656A2 (uk)
BR112021014123A2 (uk)
BR112023009656A2 (uk)
BR112022024743A2 (uk)
BR112023006729A2 (uk)
BR102021018859A2 (uk)
BR102021015500A2 (uk)
BR112023008622A2 (uk)
BR112023011738A2 (uk)
JPWO2022220227A1 (uk)
BR112023016292A2 (uk)
BR112023004146A2 (uk)
BR112023011610A2 (uk)
BR112023011539A2 (uk)
BR112023008976A2 (uk)
BR102021020147A2 (uk)
BR102021018926A2 (uk)
BR102021018167A2 (uk)
BR102021017576A2 (uk)
BR102021016837A2 (uk)
BR102021016551A2 (uk)
BR102021016375A2 (uk)
BR102021016176A2 (uk)
BR102021016200A2 (uk)

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230517

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240521

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20240917